Trump plans steep tariffs on generic drugs starting in 2028 to spur U.S. production

The Trump administration's plan to impose steep tariffs on generic drugs starting in 2028 is aimed at encouraging domestic production of these essential medicines. This move is likely to have significant implications for the pharmaceutical industry, particularly for generic drug manufacturers who currently rely heavily on overseas production. By incentivizing onshore production, the administration hopes to reduce the country's reliance on foreign suppliers and create domestic jobs.

The tariffs will likely have a mixed impact on the industry. On one hand, they may encourage some generic drugmakers to relocate their production facilities to the US, potentially creating jobs and stimulating economic growth. On the other hand, the tariffs could lead to higher costs for consumers and potentially disrupt the supply of generic drugs, which are often used to treat a wide range of conditions. Additionally, the tariffs may disproportionately affect smaller generic drug manufacturers who may not have the resources to relocate their production facilities.

Fund managers should watch how the tariffs affect the competitive landscape for generic drug manufacturers and the broader pharmaceutical industry. They should also monitor the impact on the supply chain and potential disruptions to the availability of generic drugs. Key players to watch include generic drug manufacturers such as Teva Pharmaceutical Industries, Mylan NV, and Sun Pharmaceutical Industries, as well as companies with significant US-based production facilities. The tariffs' effectiveness in spurring onshore production and the potential responses from other countries will also be important to track.

Originally reported by cnbc.com. FundNews adds analysis for finance & markets readers.